Data Roundup: June 2025 Features Updates from EHA, ASCO, and More
Catch up on any of the key data updates you may have missed last month, with coverage highlights from the CGTLive™ team.
ImmunoLogic, Episode 4: "Inflammatory Storms and Gentle Balances: Navigating Toxicities in Immunotherapies" With Caroline Diorio, MD, FRCPC, FAAP
In Episode 4 of ImmunoLogic, Caroline Diorio, MD, FRCPC, FAAP, discussed her research on adverse events associated with cell therapy.
Survival Outcomes Found to Be Comparable for Axi-Cel, Liso-Cel, and Tisa-Cel in Real World DLBCL Data
The 3 FDA-approved CAR T-cell therapies showed comparable survival outcomes in DLBCL over a 3-year period.
ImmunoLogic, Episode 3: "Breaking the Brain’s Barrier: CAR T-Cells Take on Glioblastoma" With Marcela Maus, MD, PhD
In Episode 3 of ImmunoLogic, Marcela Maus, MD, PhD, discussed her research on CAR-T for treating glioblastoma.
enGene Snags FDA RMAT Designation for Bladder Cancer Gene Therapy Detalimogene
The gene therapy is currently being evaluated in the phase 1/2 LEGEND clinical trial.
Around the Helix: Cell and Gene Therapy Company Updates – June 25, 2025
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
